News
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
* Researchers at the Danish Headache Center are testing semaglutide along with a very low calorie diet as a treatment for new ...
Danish drugmaker Novo Nordisk's stock was down nearly 20% in premarket trading Tuesday morning after the company cut its ...
Novo Nordisk appoints Maziar Mike Doustdar as the new CEO to tackle falling sales and shares amid stiff competition in the ...
Comedian and Emmy-nominated actor Kym Whitley opens up about her long journey with weight management. The "Happy Gilmore 2" ...
GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...
Experts say supplement companies have tried to capitalize on the GLP-1 craze, putting the phrase in their product names, ...
Novo Nordisk A/S (NVO) tumbled 22% Tuesday - The company attributed its lowered guidance in part to persistent use of ...
A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting ...
The first GLP-1 weight-loss drug, liraglutide (sold as Saxenda) was approved about 2014, and semaglutide, which came along in 2017, has eclipsed it. The tirzepatide drugs for weight are newer.
Weight-loss wonder drug Mounjaro/Zepbound shrinks breast cancer tumors Date: July 15, 2025 Source: The Endocrine Society Summary: A cutting-edge mouse study reveals that tirzepatide, the dual GLP ...
Nostalgic ’90s movie lovers will find it hard to forget classics like Mrs. Doubtfire, and even harder to forget Harvey ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results